S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Options Trading Plan–Perfect For Beginners (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Options Trading Plan–Perfect For Beginners (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Options Trading Plan–Perfect For Beginners (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Options Trading Plan–Perfect For Beginners (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:ICPT

Intercept Pharmaceuticals (ICPT) Stock Forecast, Price & News

$10.48
-0.32 (-2.96%)
(As of 09/22/2023 ET)
Compare
Today's Range
$9.85
$10.74
50-Day Range
$9.99
$11.86
52-Week Range
$8.82
$21.86
Volume
1.31 million shs
Average Volume
892,724 shs
Market Capitalization
$437.85 million
P/E Ratio
1.64
Dividend Yield
N/A
Price Target
$22.36

Intercept Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
113.4% Upside
$22.36 Price Target
Short Interest
Bearish
29.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.13
Upright™ Environmental Score
News Sentiment
0.30mentions of Intercept Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.06) to $2.27 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

493rd out of 963 stocks

Pharmaceutical Preparations Industry

226th out of 458 stocks


ICPT stock logo

About Intercept Pharmaceuticals (NASDAQ:ICPT) Stock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.

ICPT Price History

ICPT Stock News Headlines

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Intercept Pharma (ICPT) Receives a Hold from RBC Capital
Why CymaBay Therapeutics Stock Is Jumping Today
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
Positive Report for Intercept Pharma (ICPT) from H.C. Wainwright
RBC Capital Keeps Their Hold Rating on Intercept Pharma (ICPT)
Intercept Pharma To Cut Jobs
See More Headlines
Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Company Calendar

Last Earnings
8/02/2023
Today
9/24/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ICPT
CUSIP
45845P10
Employees
341
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.36
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+113.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$221.82 million
Pretax Margin
-51.82%

Debt

Sales & Book Value

Annual Sales
$285.71 million
Book Value
$2.25 per share

Miscellaneous

Free Float
39,192,000
Market Cap
$437.85 million
Optionable
Optionable
Beta
1.22
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Jerome B. Durso (Age 55)
    Pres, CEO & Director
    Comp: $1.37M
  • Mr. Andrew Saik (Age 54)
    Chief Financial Officer
    Comp: $888.6k
  • Mr. Jared M. Freedberg J.D. (Age 55)
    Gen. Counsel
    Comp: $812.55k
  • Ms. Linda M. Richardson (Age 59)
    Exec. VP & Chief Commercial Officer
    Comp: $837.73k
  • Dr. M. Michelle Berrey M.D. (Age 56)
    M.P.H., MPH., Pres of R&D and Chief Medical Officer
    Comp: $1.12M
  • Mr. Rocco Venezia (Age 47)
    Chief Accounting Officer & Treasurer
  • Mr. Nareg Sagherian
    Exec. Director of Global Investor Relations
  • Mr. David Ford (Age 53)
    Chief HR Officer
  • Dr. Mark Pruzanski M.D. (Age 55)
    Founder, Advisor & Director
  • Paul Nitschmann
    Sr. VP of Regulatory Affairs













ICPT Stock - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ICPT shares.
View ICPT analyst ratings
or view top-rated stocks.

What is Intercept Pharmaceuticals' stock price forecast for 2023?

8 Wall Street analysts have issued 1 year target prices for Intercept Pharmaceuticals' stock. Their ICPT share price forecasts range from $13.00 to $54.00. On average, they anticipate the company's stock price to reach $22.36 in the next year. This suggests a possible upside of 113.4% from the stock's current price.
View analysts price targets for ICPT
or view top-rated stocks among Wall Street analysts.

How have ICPT shares performed in 2023?

Intercept Pharmaceuticals' stock was trading at $12.37 on January 1st, 2023. Since then, ICPT shares have decreased by 15.3% and is now trading at $10.48.
View the best growth stocks for 2023 here
.

Are investors shorting Intercept Pharmaceuticals?

Intercept Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 10,400,000 shares, an increase of 9.2% from the August 15th total of 9,520,000 shares. Based on an average daily trading volume, of 986,900 shares, the days-to-cover ratio is currently 10.5 days. Currently, 29.0% of the company's stock are short sold.
View Intercept Pharmaceuticals' Short Interest
.

When is Intercept Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ICPT earnings forecast
.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.42. The biopharmaceutical company earned $83.70 million during the quarter, compared to analyst estimates of $79.57 million. Intercept Pharmaceuticals had a negative trailing twelve-month return on equity of 189.98% and a net margin of 68.07%. Intercept Pharmaceuticals's revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.68) EPS.

What ETF holds Intercept Pharmaceuticals' stock ?

Virtus LifeSci Biotech Products ETF holds 28,540 shares of ICPT stock, representing 1.65% of its portfolio.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $320.00 million-$340.00 million, compared to the consensus revenue estimate of $320.39 million.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.52%), State Street Corp (10.01%), Renaissance Technologies LLC (2.10%), Boothbay Fund Management LLC (0.00%), Rockefeller Capital Management L.P. (1.86%) and Geode Capital Management LLC (1.47%). Insiders that own company stock include Sandip Kapadia and Srinivas Akkaraju.
View institutional ownership trends
.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $10.48.

How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $437.85 million and generates $285.71 million in revenue each year. The biopharmaceutical company earns $221.82 million in net income (profit) each year or $6.39 on an earnings per share basis.

How many employees does Intercept Pharmaceuticals have?

The company employs 341 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001.

This page (NASDAQ:ICPT) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -